other material
confidence high
sentiment positive
materiality 0.85
Definium DT120 ODT Phase 3 Voyage study hits primary endpoint in GAD; HAM-A diff -5.4
Definium Therapeutics, Inc.
- Primary endpoint met: HAM-A LS mean change -11.6 vs placebo -6.2, placebo-adjusted -5.4 (p<0.0001, d=0.81).
- Key secondary endpoints met: CGI-S at Week 12 -0.6 (p<0.0001); HAM-A at Week 1 -7.7 (p<0.0001).
- HAM-A response rate (≥50%) 43% vs 16% (p<0.0001); remission rate (≤7) 14% vs 4% (p=0.0222).
- Safety: mild-to-moderate transient AEs, no new signals, no suicidality; mean EoSC time 6.4 hours.
- Panorama GAD topline results expected in September 2026; follows positive Emerge MDD readout in June.